Findings

What do systematic reviews say?

2,038 questions · 2,118 findings · 339 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 323 · 15.3%GRADE not reported 166 · 7.8%Very low 552 · 26.1%Low 592 · 28%Moderate 340 · 16.1%High 145 · 6.8%

Glitazone vs placebo

eGFR · people with diabetes and CKD

The review found no eligible studies for this question.

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Glitazone vs placebo

Hypoglycaemia · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 70 participants
Very low

Glitazone vs placebo

Discontinuation of medication due to adverse events · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 63 participants
Very low

Sitagliptin vs glipizide

HbA1c (%) · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 398 participants
Low

Sitagliptin vs glipizide

FBG (mmol/L) · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 397 participants
Low

Sitagliptin vs glipizide

Death (all causes) · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 551 participants
Very low

Sitagliptin vs glipizide

All cardiovascular death · people with diabetes and CKD

The review found no eligible studies for this question.

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sitagliptin vs glipizide

Weight (kg) · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 552 participants
Low

Sitagliptin vs glipizide

eGFR · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 552 participants
Low

Sitagliptin vs glipizide

Hypoglycaemia · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 551 participants
Moderate

SGLT2 inhibitors vs placebo

All cardiovascular death · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 2788 participants
Low

Sitagliptin vs glipizide

Discontinuation of medication due to adverse events · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 551 participants
Very low

SGLT2 inhibitors vs placebo

Weight (kg) · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1029 participants
Low

SGLT2 inhibitors vs placebo

eGFR · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 848 participants
Moderate

SGLT2 inhibitors vs placebo

Hypoglycaemia · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 3086 participants
Low

SGLT2 inhibitors vs placebo

Discontinuation of medication due to adverse events · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 917 participants
Very low

DPP‐4 inhibitors vs placebo

HbA1c (%) · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 867 participants
Low

Intervention not reported

LDL‐cholesterol fluvastatin 10 mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 595 participants
High

Intervention not reported

Total cholesterol fluvastatin 80 mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
27 studies · 3943 participants
High

Intervention not reported

CI: Confidence interval · participants with normal or abnormal lipid profiles

The review found no eligible studies for this question.

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found